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Carles Galisteo MD , Francisca Sivera MD, PhD ,
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José Andrés Román-Ivorra MD, PhD , Pau Lluch MD ,
Sara Manrique-Arija MD, PhD , Paloma Vela MD, PhD ,
Eugenio De Miguel MD, PhD , Carmen Torres-Martı́n MD ,
Juan Carlos Nieto MD, PhD , Carmen Ordas-Calvo MD ,
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Francisco Navarro MD, PhD , Enrique Raya MD, PhD , Eva Galindez-Agirregoikoa MD ,
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ABSTRACT  
Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis 
(GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ 














Methods: Observational, open-label multicenter study from 40 national referral centers 
of GCA patients treated with TCZ due to inefficacy or adverse events of previous therapy. 
Outcomes variables were improvement of clinical features, acute phase reactants, 
glucocorticoid-sparing effect, prolonged remission and relapses. A comparative study was 
performed: a) TCZ route (SC vs. IV); b) GCA duration (≤6 vs. >6 months); c) serious 
infections (with or without); d) ≤15 vs. >15 mg/day at TCZ onset. 
Results: 134 patients; mean age, 73.0±8.8 years. TCZ was started after a median [IQR] 
time from GCA diagnosis of 13.5 [5.0-33.5] months. Ninety-eight (73.1%) patients had 
received immunosuppressive agents. After 1 month of TCZ 93.9% experienced clinical 
improvement. Reduction of CRP from 1.7 [0.4-3.2] to 0.11 [0.05-0.5] mg/dL (p<0.0001), ESR 
from 33 [14.5-61] to 6 [2-12] mm/1st hour (p<0.0001) and decrease in patients with anemia 
from 16.4% to 3.8% (p<0.0001) were observed. Regardless of administration route or 
disease duration, clinical improvement leading to remission at 6, 12, 18, 24 months was 
observed in 55.5%, 70.4%, 69.2% and 90% of patients. Most relevant adverse side-effect 
was serious infections (10.6/100 patients-year), associated with higher doses of prednisone 
during the first three months of therapy. 
Conclusion: In clinical practice, TCZ yields a rapid and maintained improvement of 















Giant cell arteritis (GCA) is a large-vessel vasculitis (LVV) which affects medium and 
large sized arteries. It is common in European people older than 50 years as well as 
in North American of European ancestry (1-3). Although blindness is the most feared 
complication, other severe manifestations such as stroke and aneurysms can also 
occur (4-7). 
The mainstay treatment of GCA are glucocorticoids (8,9). However, adverse events 
related to these drugs are common (9-11). Besides, relapses are relative frequent in 
GCA patients (12,13). Therefore, other medications such as leflunomide, 
azathioprine or cyclophosphamide have been used with no efficacy (14-16). For 
methotrexate, results are controversial but a metaanalysis confirmed its efficacy (17) 
Although the etiology of GCA remains unknown, different proinflammatory cytokines 
including TNFα and IL-6 act as soluble pathogenic factors (18). However, 
prospective, double-blind studies with monoclonal TNFα inhibitors led to poor results 
(19). 
In contrast, several case series suggested that tocilizumab (TCZ), a humanized 
monoclonal antibody against the IL-6 receptor, may be a good therapeutic option in 
GCA (20-27). In this regard, two recent randomized clinical double-blinded Phase II 
and III studies showed efficacy of TCZ in patients with GCA (28,29). Consequently, 
TCZ has been approved by the European Medicines Agency (EMA) and the Food 
and Drug Administration (FDA) for the treatment of patients with GCA. However, it is 
not uncommon to see that patients are often excluded from clinical trials due to 
comorbidities. Also, many of the individuals included in these two trials were patients 
with a recent diagnosis of GCA and some others had a relative short period of follow-














and 119 of 251 (47%) in a Phase III study were patients with GCA of recent onset 
(28,29). In the GiACTA trial, newly diagnosed GCA was defined if diagnosis was 
done ≤ 6 weeks before baseline, with a mean± SD time between diagnosis and TCZ 
onset of 0.5±0.5 months (29). However, in a real-world scenario, TCZ will probably 
be more frequently used in patients with GCA refractory to conventional treatment or 
in those who experience side effects, including also GCA patients with one or 
several comorbidities. Therefore, in real life, patients with GCA undergoing TCZ 
therapy have longer disease duration, being often relapsing patients who are 
refractory to conventional immunosuppressive drugs. In addition, in the phase II 
study TCZ was prescribed intravenously (IV) whereas in the phase III GiACTA trial 
TCZ was given subcutaneously (SC) (28,29). Moreover, the recommended dose of 
prednisone at the onset of TCZ therapy has not clearly established. 
Taking all these considerations into account, the aim of the present study was to 
assess the usefulness and safety of TCZ in GCA patients from a real clinical setting 
with refractory disease and/or with unacceptable side effects due to conventional 
treatment. 
 
2. PATIENTS and METHODS 
2.1 Patients, Enrollment Criteria and Study protocol 
We set up an observational, retrospective open-label multicenter study that included 
134 GCA patients treated with TCZ in real clinical practice and followed-up, in some 
cases, up to 48 months. Before TCZ onset, all of them had received high-dose 
glucocorticoids, and 98 (73.1%) conventional synthetic and/or other biologic 
immunosuppressive drugs. To reduce selection bias, in the present study we 














outcome. Preliminary, partial data on 22 patients were previously reported (21). The 
study was approved by the Clinical Research Ethics Committee of University 
Hospital Marqués de Valdecilla from Santander (Cantabria, Spain). 
Patients were diagnosed with GCA at the Rheumatology or Autoimmune Units of 40 
national referrals centers. GCA diagnosis was based on a) American College of 
Rheumatology (ACR) criteria (30), b) a positive biopsy of temporal artery, and/or c) 
presence of imaging techniques consistent with large vessel vasculitis (LVV) in 
patients with cranial symptoms of GCA. The main imaging techniques used for LVV 
diagnosis were 18F-fluorodeoxyglucose positron emission tomography/computed 
tomography (18F-FDG PET/CT) scan, magnetic resonance imaging angiography 
(MRI-A), computed tomography angiography (CT-A), and helical CT scan. 
Treatment of GCA was based on the classic pharmacological therapy, starting on 
high dose of glucocorticoids, generally an initial dose of prednisone between 40 to 
60 mg/day, which was gradually tapered. Conventional immunosuppressive drugs 
and biologic therapy were used to spare glucocorticoid dose, mainly in patients with 
relapsing disease or in those cases with adverse side effect related to glucocorticoid 
therapy. The doses of conventional immunosuppressive drugs and biological agents 
used prior to TCZ were as follows: methotrexate (MTX) (7.5-30 mg/SC/week or 7.5-
25 mg/per os/week), leflunomide (LFN) (10-30 mg/per os/day), hydroxychloroquine 
(HCQ) (400 mg/per os/day), azathioprine (AZA) (50-150 mg/per os/day), 
cyclophosphamide (CYC) (75-125 mg/per os/day), mycophenolate mofetil (MMF) (2 
g/ per os/day), etanercept (ETN) (50 mg/SC/week), infliximab (IFX) (3 mg/kg/IV/8 
weeks), rituximab (RTX) (2 g/IV/6 months) and abatacept (ABT) (10 mg/kg/IV at 0, 2, 
4 weeks and later every 4 weeks). 














therapy in patients with rheumatic diseases, the presence of infectious diseases had 
to be ruled out, including tuberculosis and hepatitis B or hepatitis C infection, before 
the onset of biologic therapy, as previously described (31). 
To exclude latent tuberculosis, a tuberculin skin testing (PPD) and/or an interferon 
assay (quantiFERON) as well as a chest radiography were performed. In positive 
cases, prophylaxis with isoniazid was initiated at least 4 weeks before the onset of 
the biological agent and it was maintained for 9 months. The presence of 
malignancies was also excluded in all the patients. 
TCZ was prescribed IV at standard dose (8 mg/kg/4 weeks) or SC (162 mg/week). It 
was given due to lack of efficacy and/or unacceptable adverse side-effects related to 
previous therapy. In most cases, TCZ was prescribed off-label since it was indicated 
before its approval by the EMA and the FDA for the treatment GCA. Therefore, a 
written informed consent was obtained in these cases. 
2.2 Clinical definitions and laboratory data 
Fever was considered to be present if temperature was ≥ 38ºC. Constitutional 
symptoms included asthenia, anorexia and weight loss greater than 5% of the 
normal body weight over the last 6 months before disease diagnosis. Headache if it 
was of recent development or had different characteristics than usual. Visual 
manifestations include blurred vision, diplopia, amaurosis fugax, unilateral or bilateral 
hemianopsia and permanent unilateral or bilateral blindness. Polymyalgia 
rheumatica (PMR) was defined according to the classification criteria proposed by 
EULAR/ACR 2012 (32). Definition of other clinical manifestations were reported 
elsewhere (33).  
Serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), renal and 














onset and then at each visit. A Serum CRP value was considered to be increased 
when it was higher than 0.5 mg/dL. An ESR value greater than 20 mm/h in men or > 
25 mm/h in women was also considered abnormal. Anemia was defined as a 
hemoglobin level ≤11 g/dL.  
A serious infection was considered to be present when a life-threatening infection, 
fatal, or requiring hospitalization occurred, intravenous antibiotics were required, or 
the infectious process led to persistent or significant disability. 
Large vessel involvement was considered to be present if vasculitis involvement of 
the aorta and/or its major branches was disclosed by imaging techniques such as 
18F-FDG PET-CT scan, MRI-A, CT-A, or helical CT-scan. Assessment of large 
vessel vasculitis was performed in each of the recruiting centers. Nuclear medicine 
radiologists or angiography or angio/ interventional radiology staff members experts 
in the field from each hospital confirmed the presence of large vessel vasculitis.   
Remission was defined if the patients was free of symptoms and had normalization 
of the acute phase reactants (CRP and ESR).  
Prolonged remission was defined if the patients persisted asymptomatic with normal 
acute phase reactant for at least 6 months.  
Relapse was defined as the recurrence of signs or symptoms of GCA along with 
ESR >20 mm/h in men or >25 mm/h in women and/or serum CRP >0.5 mg/dL.    
2.3 Data collection 
Information was retrieved from the patient’s clinical records according to a specific 
designed protocol, including data on clinical and laboratory parameters at diagnosis, 
drugs used for the management of GCA, presence of relapses and side effect 














effects while patients were undergoing TCZ therapy. To minimize entry error, all the 
data were double checked. Information was stored in a computerized database. 
2.4 Statistical Analysis  
All continuous variables were tested for normality, and results were expressed as 
mean± standard deviation (SD) or as median and interquartile range (IQR) as 
appropriate. Student's t test or Mann-Whitney U-test were used to compare 
continuous variables, and 2-test to compare categorical variables.  
To assess the effect of TCZ on serum CRP levels, ESR and dose of prednisone 
between TCZ onset and the different follow-up visits we used the Wilcoxon’s signed 
rank test. 
A comparative study between the following groups was done: a) patients receiving IV 
or SC TCZ; b) TCZ efficacy in GCA patients with a disease duration ≤6 months or >6 
months; c) TCZ in GCA patients with and without serious infections; and d) patients 
receiving prednisone doses ≤15 mg/d or >15 mg/d at TCZ onset. 
Analyses were performed by using STATISTICA software (StatSoft Inc. Tulsa, 
Oklahoma, USA). 
2.5 Role of the Funding source 
This study was not funded by any drug company. It was the result of an independent 
initiative of the investigators. 
 
 3. RESULTS 
3.1 Baseline main clinical features prior to TCZ onset 
We studied 134 patients (101 women/33 men); mean age 73.0±8.8 years, diagnosed 
with GCA and treated with TCZ. Of them, 119 (88%) fulfilled the 1990 ACR 














positive temporal artery for GCA in 9 cases. Six patients did not fulfil the ACR 
classification criteria for GCA and had a negative TAB. All of them were older than 
50 years but had an ESR at the time of diagnosis lower than 50 mm/1st hour. 
Nevertheless, they presented cranial ischemic manifestations. In these patients, a 
diagnosis of GCA was confirmed by a positive imaging technique showing large 
vessel vasculitis involvement. In addition, other entities, such as connective-tissue 
diseases, IgG4 related disease or any other inflammatory conditions that may be 
associated with large-vessel vasculitis, were excluded. In addition, all of them 
exhibited a rapid response to prednisone dose (initial dose range between 40-60 
mg/day). With respect to this, a positive temporal artery biopsy was positive in 72 
(61.5%) of 117 patients in whom it was performed. Also, imaging techniques to 
identify the presence of LVV were performed in 75 patients. Of them 58 yielded 
positive results. With respect to this, 51 of these 58 patients with LVV also had 
cranial features of GCA.  
The median [IQR] time from GCA diagnosis to TCZ onset was 13.5 [5.0-33.5] 
months. The main clinical features before TCZ onset were PMR (n=73) and 
headache (n=70), followed by constitutional symptoms (n=31) and jaw claudication 
(n=14). Twenty-eight patients from this series had visual manifestations at the time 
of GCA diagnosis. Besides glucocorticoids and before starting TCZ, 98 (73.1%) 
patients had received conventional immunosuppressive drugs: MTX (n=94), AZA 
(n=14), LFN (n=9), CYC (n=4), HCQ (n=2), MMF (n=1). Five of them had also 
received other biologic agents: IFX (n=2), ETN (n=1), RTX (n=1), and ABA (n=1) 
(Table 1). The median [IQR] number of immunosuppressive agents per patient, 
before TCZ onset was 1 [0.75-1.0]. 














TCZ was initiated due to refractory GCA (n=86) or unacceptable adverse events of 
previous therapy (n=48). It was administered IV to 106 (79.1%) patients and SC to 
28 (20.9%). The initial dose was 8 mg/kg/IV/4 weeks or 162 mg/SC/week, 
respectively. The maintenance dose of TCZ ranged from 8 mg/IV/kg/4 weeks to 4 
mg/IV/kg/8 weeks, and from 162 mg/SC/ week to 162 mg/SC/3 weeks. Regardless 
of glucocorticoids, TCZ was prescribed as monotherapy to 82 (62.2%) cases and 
combined with conventional immunosuppressive agents in 52 (38.8%) patients: MTX 
(n=48), AZA (n=3), and LFN (n=1). 
As described in Table 2, one month after TCZ onset, most patients (93.9%) 
achieved clinical improvement. At that time, significant reduction of the acute phase 
reactants was also observed. In this regard, the median serum CRP fell from 1.7 
[0.4-3.2] to 0.11 [0.05-0.5] mg/dL (p<0.0001), and the median ESR from 33 [14.5-61] 
to 6 [2-12] mm/1st hour (p<0.0001). The percentage of patients with anemia 
decreased from 16.4% to 3.8% (p<0.0001), and the mean hemoglobin level 
increased from 12.3±1.5 g/dL to 13.1±1.3 g/dL (p<0001). Furthermore, the median 
dose of prednisone was reduced from 15 [10-30] to 13.75 [7.5-20] mg/day 
(p<0.0001) at month 1. Noteworthy, improvement of the clinical and laboratory 
parameters was observed throughout the follow-up. At the same time successful 
glucocorticoid tapering was achieved (Table 2 and Figure 1, panels A, B and C).  
Persistent remission of the disease was observed in 27 (69.2%) of 39 patients 
followed-up for at least 2 years. At that time, the median level of the acute phase 
reactants in these 39 patients was within the normal range. Interestingly, the median 
prednisone dose after 2 years of follow-up in these 39 patients was 0 [0-5] mg/day. 
However, 7 of these 39 cases (17.9%) had relapses during the follow-up, usually 














With respect to these 7 relapsing patients, two of them were still receiving TCZ at 24 
months of follow-up. From the remaining 5 patients, TCZ was withdrawn in 3 patients 
due to remission and because of severe adverse events in the other 2 patients. 
No significant differences in the clinical response or in the acute phase reactants 
were observed when patients were stratified according to the duration of the disease 
prior to TCZ equal to or less than 6 months or longer than 6 months. It was also the 
case when patients were compared according to the route of TCZ administration (IV 
or SC) or when patients receiving more than 15 mg/day at the time of TCZ onset 
were compared with those receiving 15 mg/day or less (Figure 2 panels B, C and 
D).   
3.3 Side effects 
After a median follow-up of 12 [3-24] months, 32 (23.9%) patients developed 
relevant adverse events (Table 3). Seventeen of them required permanent 
discontinuation of TCZ therapy. The most frequent adverse events were infections 
and hematological abnormalities. Serious infections were observed in 16 patients 
(11.9%; 10.6 per 100 patients-year).  
Five patients died during the follow-up due to stroke (n=2; one of them in the setting 
of an infective endocarditis), lung cancer (n=1), necrotizing gluteal ulcer 
(hyponatremia and cutaneous infection) (n=1), and of unknown cause (n=1). 
We performed a comparative study between patients with serious infections (n=16) 
and those without (n=118). At TCZ onset, patients who experienced serious 
infections were slightly older (74.3±9.6 vs. 72.9±8.7 years; p=0.55) and had a non-
statistically significant longer course of the disease (20 [4.25-45.8] vs. 13 [5-29.3] 
months; p=0.60). They were receiving a significantly greater prednisone dose at TCZ 














onset of TCZ (12.5 [10-20] vs. 7.5 [5.0-12.5] mg/day; p=0.003). Thirteen of the 66 
patients that received more than 15 mg/day of prednisone at TCZ onset had serious 
infections (16.3 per 100 patients-year) compared to only 3 (4.2 per 100 patients-
year) of 68 from the group on ≤15 mg/day (p=0.006). Nevertheless, clinical and 
acute phase reactants improvement was similar in both groups. 
To analyze the safety and efficacy of TCZ, we made a comparative study regarding 
associated therapies and the duration of the treatment with TCZ. The biologic agent 
was prescribed as monotherapy (82, 62.2%) or combined with conventional 
immunosuppressants (52, 38.8%). The main immunosuppressants were MTX 
(n=48), AZA (n=3), and LFN (n=1). There were not statistically significant differences 
in terms of relevant adverse events (28% vs 17.3%, p=0.55) or serious infections 
between patients treated with TCZ in monotherapy and those treated with TCZ in 
combination with a conventional immunosuppressant (14.6% vs 7.7%, p=0.227). 
Likewise, a comparison according to duration of TCZ treatment (< 12 months in 68 
[50.7%] patients and ≥ 12 months in 66 [49.3%] patients) was performed. Relevant 
adverse events were seen in 14 (20.5%) patients vs 18 (27.2%) patients 
respectively, p=0.366. More specifically, regarding serious infections, no significant 
differences were observed. In the first group (< 12 months) they occurred in 13.2% 
of patients whereas they were observed in 10.6% of the patients from the second 
group (≥ 12 months), p=0.640. 
Figure 3 shows the flow-chart summarizing the 134 patients with GCA on TCZ 
















We present the largest multicenter series of real-life GCA patients in whom short and 
long-term efficacy of TCZ was assessed. All of them were refractory and/or had 
unacceptable side effects due to conventional therapy. Our results show that TCZ 
yields a rapid and maintained clinical and laboratory improvement, regardless of 
GCA time course (≤ 6 months or > 6 months), TCZ administration route (IV vs SC) or 
prednisone dose at TCZ onset (≤ 15 mg/d or > 15 mg/day). However, the frequency 
of serious infections was higher than reported in the GiACTA clinical trial and in 
patients with rheumatoid arthritis (RA), especially in those GCA patients on higher 
doses of prednisone during the first three months of treatment (29). 
Glucocorticoids are the first line of treatment in GCA and they are usually effective at 
high doses (9,10). However, relapses are common when the dose is tapered, and 
side-effects are also frequent (9,10,12). For that reason, several synthetic 
immunosuppressive agents have been used for the treatment of GCA, but only MTX 
has shown positive although often contradictory result (10,14). Thus, the biologic 
therapy represents a new and promising alternative in the treatment of patients with 
GCA, although anti-TNFα agents showed negative results (19). 
IL-6 has a wide range of pleiotropic effects, including production of acute phase 
reactants by hepatocytes, B lymphocyte differentiation and T lymphocyte subset 
differentiation. Th1 and Th17 are involved in GCA, and IL-6 blockade may correct 
the imbalance of Th17 and/or Th1 versus Treg lymphocytes (18,34-38). 
TCZ is a humanized monoclonal antibody acting against soluble and membrane 
bound IL-6 receptor. TCZ has been approved for the treatment of inflammatory and 
autoimmune diseases, such as RA, systemic and polyarticular juvenile arthritis and 














evidence supports the potential use of TCZ in other autoimmune diseases such as 
uveitis and adult-onset Still’s disease (34,39-42). 
Several observational studies on the use of TCZ in GCA showed promising results, 
with clinical and laboratory data improvement and a glucocorticoid dose sparing (20-
22, 23-27,43,44). Interestingly, a phase II, randomized, double-blind, placebo-
controlled trial showed complete GCA clinical remission at week 12 in 85% of 
patients treated with TCZ (8 mg/kg/4 weeks IV), and a relapse-free survival in the 
same extent at week 52, with less cumulative glucocorticoid dose (28). Results of the 
GiACTA study (29), a phase III, randomized, double-blind placebo-controlled trial, 
showed that the use of TCZ at a dose of 162 mg SC weekly or every other week 
(eow), plus a 26-week prednisone tapering regimen, allowed sustained remission in 
56% and 53% of patients respectively, at 52 weeks. A decrease of the total 
cumulative dose of glucocorticoids was also possible (29).  
However, clinical trials do not always exemplify a real-world clinical scenario, since 
they often include selected patients with very specific inclusion and exclusion criteria 
and limited follow-up over time. For example, patients with specific comorbidities are 
usually excluded and only a small proportion of patients included in the GiACTA 
trials had previously received immunosuppressive drugs (29). On the other hand, 
information on the long-term efficacy and safety of TCZ in GCA patients treated in 
daily clinical practice is scarce. In this regard, the overall safety profile of TCZ in 
GCA is consistent with the known safety in other conditions such as RA (45). In the 
GiACTA study (29), serious infections occurred in 7% of the patients that received 
TCZ weekly, 4% in the group on TCZ eow and 4% in the group that followed the 26-
week tapering protocol (29). In our series, serious infections occurred in 11.9% of 














RA patients was 4.7 per 100 patients-year (45). The older age as well as the higher 
prednisone dose used in our series of GCA patients at the time of TCZ onset may 
explain the increased frequency of serious infections when compared with RA.  
Therefore, we feel that several features of the patient should be considered before 
using TCZ in the clinical practice. They include the age at the beginning of therapy, 
the cumulative dose of corticosteroids and the presence of comorbidities that 
predispose to infections.   
Our study represents the largest real-world study on refractory GCA treated with 
TCZ. However, it has potential limitations derived from its observational and 
retrospective nature. In addition, during the follow-up several patients were lost. 
Moreover, although the study included 134 cases, only 39 of them reached a follow-
up of 24 months. Also, in our study we did not use TCZ in newly diagnosed patients, 
but only in those who were refractory to conventional therapy; being this a limitation 
when compared with the GiACTA trial. Another limitation of this study was that the 
definition of relapse used by authors might not be accurate for a study assessing the 
efficacy of TCZ since this monoclonal antibody acts suppressing CRP, ESR and 
fibrinogen. This limitation was also present in the GiACTA trial. However, in an 
attempt to compare real life data with the GiACTA trial, the investigators of our study 
decided to include in the definition of relapse the presence of an increase of acute 
phase proteins, in a similar way to that used in the GiACTA trial.  
Our results are consistent with those observed in clinical trials, confirming the 
efficacy of TCZ in the treatment of GCA. Interestingly, in our series clinical and 
laboratory improvement was unrelated to disease duration, administration route or a 
















Taken together our findings and the results of the randomized control trials, TCZ 
seems to be an excellent therapeutic option in GCA, regardless of the administration 
route and GCA duration, helping to minimize the glucocorticoid exposure over time. 
The most relevant side effects are serious infections that seem to be higher than in 
the GiACTA trial.  
In conclusion, TCZ improves clinical manifestations, acute-phase reactants and 
imaging findings. However, GCA patients treated with TCZ may have normal levels 
of CRP even though active disease may be still present. Therefore; an important 
issue to be addressed is how we can be sure that TCZ-treated patients have a “true” 
remission of the disease. Therefore, we feel that the definition of relapse in future 
studies on patients undergoing biologic therapy, in particular in those treated with 
anti-IL-6 receptor agents, should be reconsidered. Because of that, based on 
previous observations of our group (46), the definition of relapses in patients 
undergoing biologic therapy should be based on the presence of clinical features and 
confirmed by an imaging technique (for example a PET/CT-scan). 
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FIGURE 1.  Reduction of acute phase reactants and glucocorticoid dose in 134 
patients with refractory giant cell arteritis (GCA) following tocilizumab therapy. A) 
Serum C-reactive protein (CRP) evolution; B) Erythrocyte sedimentation rate (ESR); 
C) Glucocorticoid dose. Bars represent median values with 95% confidence 















FIGURE 2. Percentage of responders according to clinical and/or therapeutic 
characteristics (n=134). A) In the whole series; B) According to type of therapy (IV or 
SC tocilizumab administration); C) According to giant cell arteritis (GCA) duration (≤6 
months or >6 months); D) Regarding prednisone dose at tocilizumab onset (≤15 


































TABLE 1. Main features of 134 patients with refractory Giant Cell Arteritis who were 
treated with TCZ. 
 Overall 
n= 134 
GCA fulfilling ACR 
1990 criteria n= 119 
Biopsy-proven  
GCA n= 72 
Cranial symptoms 
plus LVV* n= 51 
Age, years, mean± SD  73 ± 8.8 73.4 ± 8.5 75.7 ± 7.1 71.5 ± 8.9 
Sex, female/male n (%) 101 / 33 88 / 31 57 / 15 43 / 8 
Time from GCA diagnosis to TCZ onset (months), median [IQR] 13.5 [5.0-33.5] 14.0 [5.0-35.0] 14.5 [6.5-44.8] 14.0 [7.0-35.8] 
SYSTEMIC MANIFESTATIONS     
Fever, n (%) 9 (6.7%) 8 (6.7%) 4 (5.5%) 4 (7.8%) 
Constitutional syndrome, n (%) 31 (23.1%) 25 (21%) 14 (19.4%) 11 (21.6%) 
PMR, n (%) 73 (54.4%) 73 (61.3%) 40 (55.5%) 29 (56.8%) 
ISCHEMIC MANIFESTATIONS      
Headache, n (%) 70 (52.2%) 64 (53.7%) 33 (45.8%) 29 (56.8%) 
Jaw claudication, n (%)  14 (10.4%) 12 (10.0%) 11 (15.2%) 6 (11.7%)) 
Stroke, n (%) 1 (0.7%) - - 1 (1.9%) 
Visual involvement, n (%)  28 (20.9%) 17 (14.2%) 13 (18%) 7 (13.7%) 
AORTITIS AND ANOTHER LVV involvement, n (%) 58 (43.2%) 46 (38.6%) 36 (50.0%) 51 (100%) 
ACUTE PHASE REACTANTS at the onset of TCZ      
ESR, mm/1
st
 hour, mean (SD) 40.5 ± 31.2 39.3 ± 31.2 39.3 ± 31.2 40.5 ± 33.6 
CRP, mg/dL mean (SD) 3 ± 5.3 3.3 ± 5.6 3.2 ± 6.5 4.2 ± 7.6 
Hemoglobin, g/dL, mean (SD) 12.3 ± 1.5 12.2 ± 1.4 12.2 ± 1.4 12 ± 1.2 
POSITIVE TEMPORAL ARTERY BIOPSY, n (%) 72 (53.7%) 64 (53.7%) 72 (100%) 35 (68.6%) 
IMAGING TECHNIQUES     
Positive CTA, n/n performed (%) 4/9 (44.4%) 4/9 (44.4%) 2/5 (40.0%) 3/5 (60.0%) 
Positive PET/CT, n/n performed (%) 52/57 (91.2%) 43/47 (91.5%) 30/31 (96.8%) 46/46 (100%) 
Positive MRA, n/n performed (%) 9/12 (75%) 8/11 (72.7%) 3/5 (60%) 2/4 (50%) 
Patients with previous traditional DMARDs, n (%) 98 (73.1%) 85 (71.4%) 51 (70.8%) 42 (82.3%) 
MTX, n (%) 94 (70.1%) 82 (68.9%) 51 (70.8%) 32 (62.7%) 
AZA, n (%) 14 (10.4%) 14 (11.7%) 4 (5.5%) 6 (11.7%) 
LFN, n (%) 9 (6.7%) 8 (6.7%) 2 (2.7%) 2 (3.9%) 
CYC, n (%) 4 (2.9%) 3 (2.5 %) 2 (2.7%) 1 (1.9%) 
HCQ/CQ, n (%) 2 (1.4%) 2 (1.6%) - 1 (1.9%) 
MMF n (%) 1 (0.7%) 1 (0.8%) - - 
Patients with previous biologic therapy, n (%) 3 (2.2%) 4 (3.3%) 2 (2.7%) 1 (1.9%) 
IFX, n (%) 2 (1.4%) 2 (1.6%) 1 (1.3%) - 
ETN, n (%) 1 (0.7%) 1 (0.8%) 1 (1.3%) 1 (1.9%) 
RTX, n (%) 1 (0.7%) 1 (0.8%) 1 (1.3%) - 
ABA, n (%) 1 (0.7%) 1 (0.8%) 1 (1.3%) - 
CORTICOSTEROIDS AT TCZ ONSET     
Patients on corticosteroids, n (%) 129 (96.2%) 116 (97.4%) 69 (95.8%) 48 (94.1%) 
Prednisone dose, mg/d 21.7±16.1 21.7 ±15.6 22.0 ±15.6 19.2 ±15.5 
* Cranial symptoms of giant cell arteritis plus large vessel vasculitis (LVV) by imaging techniques.  
Abbreviatios: ABA: abatacept; ACR: American College of Rheumatology; AZA: azathioprine; CQ: cloroquine; CRP: C-reactive 
protein; CTA: computed tomography angiography; CYC: cyclophosphamide; ESR: erythrocyte sedimentation rate; ETN: 
etanercept; GCA: giant cell arteritis; HCQ: hydroxychloroquine; IFX: infliximab; LFN: leflunomide; LVV: large vessel vasculitis; 
MMF: mycophenolate mofetil; MRA: magnetic resonance angiography; MTX: methotrexate; n: number; PET/CT: positron 















TABLE 2. Main outcome variables of 134 patients with refractory Giant Cell Arteritis 
















Clinical improvement, % 













Laboratory improvement        
CRP (mg/dL), median [IQR]  
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Anemia (<11.0 g/dL), % 















Prolonged remission † %, 















Relapses ‡ %, 















Prednisone dose, median 
[IQR] 
















Abbreviations (in alphabetical order): CRP: C-reactive protein (mg/dL); ESR: erythrocyte sedimentation rate (mm/
1st
 hour); IQR: 
interquartile range; n: number;  
*p <0.01 vs. baseline (Wilcoxon test).  
† Prolonged remission: remission was considered by absence of clinical symptoms and signs and normalization of the acute phase 
reactants (CRP and ESR) for at least 6 months. ESR <20 or 25 mm/h (in men and women, respectively) and/or CRP <0.5 mg/dL were 
considered normal.  














TABLE 3. Relevant adverse events observed in our series of 134 patients with 
refractory Giant Cell Arteritis in treatment with tocilizumab. 
 
 TCZ withdrawal (n=21) Reduction TCZ dose (n=11) 
 Permanent (n=17) Transient (n=4)  
INFECTIONS    
    Cytomegalovirus (bilateral pneumonia)  1 (4.8%) - - 
    Endocarditis  1 (4.8%) 
*
 - - 
   Facial Herpes Zoster Infection † - 2 (40.0%) - 
   Bacterial Infective Bursitis
 
† - 1 (20.0%) - 
   Severe Infectious Cellulitis † - - 1 (7.7%) 
   Infectious Meningitis  1 (4.8%) - - 
   Infected ulcer
 
† 1 (4.8%) - - 
   Infected Necrotizing ulcer 1 (4.8%) 
*
 - - 
   Pneumonia 3 (14.3%) - - 
   Recurrent urinary infection and sepsis † - 1 (20.0%) 1 (7.7%) 
   Urinary sepsis 1 (4.8%) - 1 (7.7%) 
   Anal abscess ‡ - 1 (20.0%) - 
HEMATOLOGICAL ALTERATIONS
 
§    
   Bicytopenia (anemia grade III & leukopenia gr. III) - -  1 (7.7%) 
   Myelodysplastic syndrome 1 (4.8%) - - 
   Neutropenia grade IV 1 (4.8%) - 3 (23.1%) 
   Leukopenia grade III - - 1 (7.7%) 
   Thrombocytopenia grade III - - 1 (7.7%) 
NEOPLASIA  -  
   Colon adenocarcinoma 1 (4.8%) - - 
   Lung cancer  1 (4.8%) 
*
   
CARDIOVASCULAR  -  
   Atrioventricular blockade 1 (4.8%) - - 
   Hypertensive crisis 1 (4.8%) - - 
OTHERS  -  
   Alzheimer´s disease 1 (4.8%) - - 
   Diverticulitis - - 1 (7.7%) 
   Liver toxicity 1 (4.8%) - 3 (23.1%) 
   Myopathy 1 (4.8%) - - 
   Stroke 2 (9.5%) 
*
   
   Unexpected death 1 (4.8) 
*
   
These data are of adverse events, six patients presented more than one side-effect. 
* Causes of death 
† Requiring hospitalization and intravenous antibiotics 
‡ Requiring surgical drainage  
§ Cytopenias grade III were classified if hemoglobin was < 7.9 g/dL, leucocytes < 1900/mm
3
, and/or platelet count < 
49000/mm
3
. Neutropenia grade IV was considered if neutrophils < 500/mm
3
. 
